Research Article ISSN 2689-1050

Chemical & Pharmaceutical Research

Recent Trends in Nano Drug Delivery Systems for Cancer Treatment

Brianna Burnsworth, Sneed KB and Yashwant Pathak*

Taneja College of Pharmacy, University of South Florida, Tampa, Florida, USA.

***Correspondence:**
Yashwant Pathak, Taneja College of Pharmacy, University of South Florida, Tampa, Florida, USA.

Received: 05 Jan 2025; **Accepted:** 10 Feb 2025; **Published:** 20 Feb 2025

Citation: Brianna Burnsworth, Sneed KB, Yashwant Pathak. Recent Trends in Nano Drug Delivery Systems for Cancer Treatment. Chem Pharm Res. 2025; 7(1): 1-8.

ABSTRACT

Nanotechnology has revolutionized cancer therapy by enabling precise drug delivery systems that enhance therapeutic efficacy while minimizing side effects. This review explores recent advancements in nano-drug delivery systems targeting breast, prostate, and brain cancers. It delves into various nanocarrier platforms, including liposomal, polymeric, and magnetic systems, highlighting their design, functionality, and clinical applications.

The discussion encompasses the challenges associated with these nanocarriers, such as biocompatibility, targeted delivery, and overcoming biological barriers. By examining current research and clinical trials, this paper provides a comprehensive overview of the transformative potential of nanotechnology in cancer treatment. Future perspectives on personalized nanomedicine and multifunctional nanoparticles are also presented.

Keywords

Recent trends, Nano drug delivery systems, Cancer treatments, Liposomal Nano Systems, Polymeric Nano Systems, Magnetic Nano systems, Gold Nanoparticle for Cancer Therapy, Future trends.

Introduction

Cancer continues to pose a significant global health challenge, claiming approximately 10 million lives annually according to recent estimates by the World Health Organization (2020). Despite substantial advancements in medical technology, traditional cancer therapies, including surgery, chemotherapy, and radiation therapy, remain the primary treatment modalities. However, these approaches are frequently associated with limitations such as poor specificity, systemic toxicity, and the inability to prevent metastasis, leading to suboptimal patient outcomes and reduced quality of life (Cancer Biology & Medicine, 2017). For instance, chemotherapeutic drugs, while potent, often affect healthy cells, resulting in severe side effects, including immunosuppression and organ damage (SpringerLink, 2024).

The field of nanotechnology has emerged as a transformative tool in addressing these limitations, offering novel solutions that enhance the precision and efficiency of cancer treatments (Molecular Cancer, 2023). Nanotechnology enables the design of nanoscale materials and devices that can interact with biological systems at the molecular level. These nanomaterials exhibit unique physicochemical properties, such as high surface-area-to-volume ratios, tunable surface chemistry, and enhanced permeability and retention (EPR) effects, which make them ideal for targeted drug delivery applications (Nature Reviews Cancer, 2018). By capitalizing on these properties, researchers have developed nanodrug delivery systems that selectively target cancer cells, thereby improving therapeutic efficacy while minimizing systemic toxicity (MDPI, 2023).

Nanocarriers, such as liposomes, polymeric nanoparticles, and magnetic nanoparticles, are among the most extensively studied platforms in this domain. Liposomes, spherical vesicles composed of lipid bilayers, have demonstrated exceptional biocompatibility and the ability to encapsulate a wide range of therapeutic agents (Molecular Pharmaceutics, 2020). Advances in liposomal technology have led to the development of stimuli-responsive liposomes, which release their drug payload in response to specific

triggers, such as pH changes in the tumor microenvironment (Advanced Materials, 2020). Polymeric nanoparticles, constructed from biodegradable materials such as poly (lactic-co-glycolic acid) (PLGA), offer controlled and sustained drug release, making them suitable for prolonged treatments (Biomacromolecules, 2021). Magnetic nanoparticles, often composed of iron oxide, provide dual functionality by serving as both drug carriers and agents for magnetic hyperthermia, a technique that destroys cancer cells through localized heat generation (*Nanomedicine, 2019*).

Breast, prostate, and brain cancers have been focal points for nanotechnology research due to their unique challenges and high mortality rates. Breast cancer, the most frequently diagnosed cancer in women, is known for its heterogeneity and propensity for metastasis, which complicate treatment strategies *(Nature, 2023)*. Nanotechnology has facilitated the development of targeted therapies that selectively attack HER2-positive breast cancer cells, minimizing damage to surrounding healthy tissue *(Journal of Drug Delivery Science and Technology, 2019)*. Prostate cancer, a leading cause of cancer related mortality in men, often progresses to advanced stages that are resistant to conventional treatments. Nanodrug delivery systems, such as polymeric nanoparticles encapsulating chemotherapeutic agents, have shown promise in overcoming drug resistance by enhancing drug retention in prostate tumors *(Drug Discovery Today, 2020)*. Brain cancers, particularly glioblastoma, present a formidable challenge due to the bloodbrain barrier (BBB), which limits the delivery of therapeutic agents to the brain. Nanosystems engineered to traverse the BBB have opened new avenues for the treatment of these aggressive cancers (*Journal of Controlled Release, 2019)*.

The clinical translation of nanotechnology-based drug delivery systems has seen remarkable progress, with several formulations achieving regulatory approval or advancing to late-stage clinical trials. For example, liposomal doxorubicin (Doxil) has been approved for the treatment of various cancers, including ovarian and breast cancers, and serves as a model for the potential of nanotechnology in oncology *(Molecular Pharmaceutics, 2021)*. However, challenges such as scalability, reproducibility, and regulatory compliance continue to hinder the widespread adoption of nanomedicine. Addressing these challenges requires multidisciplinary collaboration among scientists, clinicians, and regulatory agencies to ensure the safe and effective integration of nanotechnology into clinical practice *(ACS Nano, 2018)*.

This review aims to provide a comprehensive analysis of recent trends in nano drug delivery systems, with a specific focus on their applications in breast, prostate, and brain cancers. The discussion will encompass the design principles, advantages, limitations, and clinical progress of various nanocarriers, such as liposomal, polymeric, and magnetic nanoparticles. Furthermore, the review will highlight emerging strategies to overcome biological and logistical challenges, including the use of artificial intelligence (AI) to optimize nanocarrier design and the integration of theragnostic to enable real-time monitoring of treatment efficacy *(Advanced Science, 2021)*. By examining these aspects, this paper seeks to underscore the transformative potential of nanotechnology in improving cancer treatment outcomes and shaping the future of precision medicine.

The potential for nanodrug delivery systems to enable combination therapies is another area of significant interest. These systems can co-deliver multiple therapeutic agents, such as chemotherapeutics and immunomodulators, to exploit synergistic effects and overcome treatment resistance *(Biomaterials, 2020)*. For instance, liposomal platforms have been designed to deliver both doxorubicin and siRNA, achieving simultaneous gene silencing and chemotherapeutic action in breast cancer models *(Journal of Nanoscience and Nanotechnology, 2020)*. Similarly, polymeric nanoparticles loaded with a combination of paclitaxel and curcumin have demonstrated enhanced efficacy in prostate cancer treatment by targeting multiple cancer pathways *(European Journal of Pharmaceutics and Biopharmaceutics, 2021)*.

Despite these advancements, the translation of nano drug delivery systems from bench to bedside remains fraught with challenges. The scalability of nanoparticle production, ensuring batch-to-batch consistency, and addressing long-term safety concerns are critical issues that need to be resolved *(Critical Reviews in Biotechnology, 2019)*. Additionally, the regulatory landscape for nanomedicine is still evolving, with agencies like the FDA and EMA working to establish standardized guidelines for the evaluation and approval of nanotechnology-based therapeutics *(Nature Nanotechnology, 2018)*. Overcoming these challenges will require sustained investment in research, infrastructure, and policy development.

Liposomal Nano Systems

Liposomal nanoparticles are spherical vesicles made up of lipid bilayers, capable of encapsulating both hydrophilic and hydrophobic drugs. This dual encapsulation ability is a critical advantage, as it allows the delivery of a wide range of drugs, regardless of their solubility profiles *(Molecular Pharmaceutics, 2020)*. Their biocompatibility, low toxicity, and ability to enhance the solubility of poorly water-soluble drugs make them particularly attractive for cancer therapy *(Nanomedicine, 2019).*

Recent advancements in liposomal nanocarriers include the development of stimuli-responsive liposomes that release their therapeutic payload in response to specific triggers such as pH changes, temperature variations, or enzymatic activity. For example, pH-sensitive liposomes have been engineered to exploit the acidic microenvironment of tumors, enabling the controlled release of drugs directly at the tumor site (*Advanced Materials, 2020)*. This targeted delivery mechanism significantly reduces systemic side effects, such as nausea, fatigue, and immune suppression, commonly associated with chemotherapy *(Nature, 2023)*.

Further innovation in liposomal systems includes functionalized liposomes, which are conjugated with targeting ligands such as antibodies, peptides, or small molecules. These functionalized systems enhance the specificity of liposomes for cancer cells by

binding to overexpressed receptors on the tumor surface, such as HER2 in breast cancer (*Journal of Drug Targeting, 2020)*. Moreover, multifunctional liposomes incorporating imaging agents, such as quantum dots or fluorescent dyes, are now being developed for theragnostic applications, enabling simultaneous therapy and monitoring of drug distribution in real time *(Nanomaterials, 2021)*.

Another critical advancement is the design of long-circulating liposomes through the incorporation of polyethylene glycol (PEG) on their surface. This "PEGylation" reduces recognition and clearance by the immune system, thereby extending the systemic circulation time of liposomes *(Biomaterials, 2020)*. For instance, Doxil, a PEGylated liposomal formulation of doxorubicin, has shown remarkable efficacy in treating ovarian and breast cancers, demonstrating the clinical potential of liposomal systems *(Molecular Cancer, 2023)*. Despite their numerous advantages, liposomal systems face challenges such as scalability, stability during storage, and high manufacturing costs. Ongoing research aims to optimize these systems by improving lipid composition, enhancing drug loading efficiency, and ensuring consistent batch-to-batch production for regulatory compliance *(Advanced Drug Delivery Reviews, 2019)*.

Polymeric Nano Systems

Polymeric nanoparticles, constructed from biodegradable polymers such as poly (lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), and polycaprolactone (PCL), offer unique advantages in drug delivery due to their tunable properties. These nanoparticles can be engineered to achieve controlled and sustained drug release, improving the pharmacokinetic profile of encapsulated therapeutic agents *(Biomacromolecules, 2021)*. Their versatility allows the delivery of a wide range of molecules, including small-molecule drugs, proteins, peptides, and nucleic acids *(Journal of Controlled Release, 2019)*.

One of the most significant advancements in polymeric systems is their ability to overcome multidrug resistance (MDR) in cancer therapy. MDR often arises due to the overexpression of efflux transporters such as P-glycoprotein, which pumps chemotherapeutic agents out of cancer cells, reducing drug efficacy *(Critical Reviews in Biotechnology, 2019)*. Polymeric nanoparticles encapsulating drugs like paclitaxel have been shown to bypass these efflux pumps, leading to higher intracellular drug concentrations and improved treatment outcomes *(Drug Discovery Today, 2020)*.

Additionally, polymeric nanoparticles have been designed to respond to environmental triggers such as pH, redox conditions, and enzymatic activity. For instance, PLGA nanoparticles containing doxorubicin have been engineered to release their payload in response to acidic pH conditions found in tumor tissues, thereby minimizing off-target effects *(Advanced Science, 2021)*. Similarly, redox-sensitive polymeric systems utilize the high glutathione levels in cancer cells to achieve selective drug release, enhancing therapeutic efficacy *(European Journal of Pharmaceutics and Biopharmaceutics, 2021)*.

Another promising application is in the delivery of nucleic acids such as siRNA, miRNA, and DNA for gene therapy. Polymeric nanoparticles have been shown to protect nucleic acids from degradation in the bloodstream and facilitate their intracellular delivery, offering new avenues for targeting oncogenes and reversing drug resistance mechanisms *(Molecular Pharmaceutics, 2021)*. Despite these advancements, challenges such as large-scale manufacturing, reproducibility, and potential toxicity of degradation byproducts remain significant barriers to the clinical translation of polymeric nanoparticles. Future research is focused on developing green synthesis methods, improving biocompatibility, and ensuring regulatory compliance *(Nanotechnology, 2020)*.

Magnetic Nanosystems

Magnetic nanoparticles, typically composed of iron oxide, have gained attention for their dual functionality in cancer therapy and diagnostics. These nanoparticles can be directed to tumor sites using external magnetic fields, ensuring precise and localized drug delivery *(Nanomedicine, 2019)*. Their magnetic properties also enable applications in imaging techniques such as magnetic resonance imaging (MRI), making them valuable tools for cancer theragnostic *(Molecular Imaging and Biology, 2020)*.

One of the most promising applications of magnetic nanoparticles is in magnetic hyperthermia therapy. In this approach, magnetic nanoparticles are introduced into the tumor site and exposed to an alternating magnetic field, generating localized heat that destroys cancer cells without harming surrounding healthy tissues *(Nanomaterials, 2021)*. When combined with chemotherapeutic agents, magnetic nanoparticles offer a synergistic effect, enhancing therapeutic efficacy through both thermal ablation and drug action *(Journal of Nanoparticle Research, 2020)*.

Recent studies have explored the use of magnetic nanoparticles in combination with immunotherapy. By delivering immune checkpoint inhibitors or cytokines directly to the tumor microenvironment, magnetic nanoparticles can stimulate the immune system to recognize and attack cancer cells more effectively *(Trends in Biotechnology, 2021).* Additionally, researchers are developing multifunctional magnetic nanoparticles that combine drug delivery, imaging, and hyperthermia capabilities into a single platform, streamlining treatment and monitoring processes *(Advanced Materials, 2020)*. While magnetic nanoparticles show great promise, their clinical translation faces challenges such as ensuring biocompatibility, avoiding aggregation, and achieving uniform particle size distributions. Moreover, concerns regarding the long-term accumulation of magnetic particles in the body and their potential toxicity must be addressed through rigorous preclinical and clinical testing *(Nature Nanotechnology, 2018).* Future directions in magnetic nanoparticles include the development of hybrid systems incorporating other nanocarriers, such as liposomes or polymeric particles, to enhance drug loading capacity and therapeutic precision. Advances in magnetic field technology and imaging techniques are also expected to further

optimize the application of magnetic nanoparticles in cancer therapy *(Journal of Controlled Release, 2021)*.

Gold Nanoparticle for Cancer Therapy

Gold nanoparticles (AuNPs) have emerged as a promising addition to the array of nanocarrier platforms, offering unique capabilities for targeted cancer therapy and diagnostics. Their appeal lies in their customizable size, shape, and surface chemistry, along with their strong optical properties, which enable them to function as both therapeutic agents and diagnostic tools. This dual functionality has positioned AuNPs as an essential component in the growing field of theragnostic, a core focus in recent trends of nano drug delivery systems *(Chemical Society Reviews, 2019)*. One of the primary applications of AuNPs in cancer treatment is their role in photothermal therapy (PTT). Unlike conventional approaches, PTT leverages the ability of AuNPs to convert absorbed near-infrared (NIR) light into heat, selectively destroying cancer cells while sparing healthy tissues. This technique is particularly advantageous for solid tumors, such as those in breast or prostate cancer, which are otherwise difficult to treat using standard therapies *(Nano Today, 2020)*. Studies have demonstrated that NIR activated AuNPs can penetrate deep tumor sites and achieve highly localized cytotoxic effects, effectively reducing tumor sizes and minimizing systemic side effects *(Advanced Drug Delivery Reviews, 2019)*.

Additionally, gold nanoparticles offer tremendous versatility as carriers for chemotherapeutic drugs. Their high surface area allows for the attachment of multiple therapeutic agents, including small-molecule drugs like doxorubicin and targeted ligands such as peptides, antibodies, or aptamers. These functionalized AuNPs are specifically designed to bind to overexpressed cancer cell receptors, such as HER2 in breast cancer or folate receptors in ovarian cancer, enhancing cellular uptake and ensuring precise drug delivery. For instance, studies have shown that doxorubicin-loaded AuNPs conjugated with folic acid achieved superior tumor targeting compared to traditional delivery methods, leading to improved efficacy and reduced toxicity *(European Journal of Pharmaceutics and Biopharmaceutics, 2021)*.

Another key advantage of AuNPs lies in their ability to integrate diagnostic capabilities with therapeutic functions, a hallmark of theragnostic. Gold nanoparticles' strong surface plasmon resonance (SPR) enables them to scatter and absorb light effectively, making them ideal for optical imaging and photoacoustic imaging. These imaging capabilities allow real-time monitoring of drug distribution and tumor progression, providing clinicians with valuable insights into treatment efficacy *(ACS Nano, 2020)*. Moreover, AuNPs have been coupled with radiolabels or fluorescent dyes to enhance imaging sensitivity in techniques like computed tomography (CT) and magnetic resonance imaging (MRI), further strengthening their diagnostic potential *(Molecular Cancer, 2023)*.

Combination therapies involving AuNPs have also gained significant traction in recent years. By simultaneously enabling photothermal therapy and drug delivery, AuNPs provide a synergistic approach to cancer treatment. For example, paclitaxel-loaded gold nanoparticles have been successfully tested in combination with PTT, showing superior tumor eradication in breast cancer models. This dual approach not only enhances therapeutic efficacy but also helps in overcoming resistance mechanisms commonly observed in advanced cancers *(Biomacromolecules, 2021)*. Despite their many advantages, the clinical translation of gold nanoparticles faces challenges. One major concern is their potential long-term accumulation in the body, which could result in toxicity or chronic inflammation. To address this, researchers are exploring the development of biodegradable AuNPs and biocompatible surface coatings that enhance clearance through natural metabolic pathways *(Journal of Nanomedicine, 2020)*. Moreover, scalability remains an issue, as the synthesis of uniformly sized and shaped nanoparticles at an industrial scale is complex and cost intensive. Innovations in green chemistry and automated nanoparticle production methods are expected to overcome these barriers *(Critical Reviews in Biotechnology, 2019)*. Looking forward, gold nanoparticles are poised to play an increasingly important role in cancer treatment as advancements in artificial intelligence (AI) and nanomaterial engineering continue to evolve. AI-driven design platforms can optimize the size, shape, and surface chemistry of AuNPs to enhance their targeting efficiency and therapeutic effects. Furthermore, the integration of gold nanoparticles into multifunctional nanoplatforms that combine photothermal therapy, chemotherapy, and diagnostic imaging represents a significant step toward achieving the goals of precision medicine *(Nature Reviews Cancer, 2018)*. These advancements are expected to address the current limitations and ensure the widespread adoption of AuNP-based therapies in clinical oncology.

Conclusion

Nanodrug delivery systems have revolutionized the landscape of cancer treatment by introducing precise, efficient, and multifunctional therapeutic options. Platforms such as liposomal, polymeric, magnetic, and gold nanoparticles have demonstrated their ability to enhance the therapeutic index of anticancer drugs, reduce systemic toxicity, and enable targeted delivery to tumor sites. These advancements not only address the long-standing challenges of traditional cancer therapies, such as poor specificity and adverse side effects but also provide new opportunities for integrating diagnostic and therapeutic modalities into a single platform through theragnostic. The progress made in this field underscores the transformative potential of nanotechnology in redefining cancer treatment paradigms and improving patient outcomes.

Among these platforms, liposomal systems stand out for their established clinical success, as evidenced by the approval of formulations like Doxil, which have set a benchmark for the safety and efficacy of nanodrug delivery systems. Similarly, polymeric nanoparticles have demonstrated versatility in encapsulating a wide range of therapeutic agents and overcoming multidrug resistance, a critical hurdle in cancer therapy. Magnetic nanoparticles have expanded the scope of cancer treatment through their ability to combine drug delivery with magnetic hyperthermia

and imaging capabilities, offering dual functionality that enhances therapeutic outcomes. Gold nanoparticles, with their unique optical and photothermal properties, have opened new avenues for combination therapies and real-time treatment monitoring, further advancing the field of precision medicine.

Despite these successes, several challenges remain that need to be addressed to fully realize the clinical potential of nano drug delivery systems. Issues such as scalability, reproducibility, biocompatibility, and long-term safety continue to hinder the widespread adoption of these technologies. For example, achieving consistent and cost effective manufacturing processes for nanoparticles is essential to facilitate their largescale production and regulatory approval. Moreover, concerns regarding the accumulation of certain nanomaterials in the body and their potential toxicity highlight the need for the development of biodegradable and biocompatible alternatives. Addressing these challenges will require collaborative efforts among researchers, clinicians, and regulatory bodies to establish standardized protocols and ensure the safe and effective integration of nanotechnology into clinical practice.

Looking ahead, the future of nanodrug delivery systems lies in the convergence of advanced nanotechnology with other cutting-edge fields, such as artificial intelligence, genomics, and immunotherapy. AI-driven design platforms have the potential to optimize the size, shape, and surface chemistry of nanocarriers, enabling personalized treatment approaches tailored to individual patient profiles. Similarly, the integration of nanotechnology with gene editing tools such as CRISPR and RNA-based therapies could open new frontiers in targeting cancer at the genetic level. Multifunctional nanoparticles that combine therapeutic and diagnostic capabilities, known as theragnostic, are expected to play a pivotal role in achieving precision oncology by providing real-time feedback on treatment efficacy and enabling dynamic adjustments to therapeutic regimens.

Moreover, the application of nanotechnology in combination therapies offers a promising strategy for tackling complex and resistant cancers. By co-delivering chemotherapeutic agents with immunomodulators or leveraging photothermal and photodynamic therapies, nanocarriers can enhance therapeutic efficacy and overcome resistance mechanisms. The development of hybrid nanosystems that integrate multiple functionalities, such as imaging, therapy, and immune activation, represents an exciting frontier in cancer treatment.

Nanodrug delivery systems have ushered in a new era of innovation in cancer therapy, with the potential to significantly improve treatment outcomes and patient quality of life. While challenges remain, ongoing advancements in nanomaterials, manufacturing technologies, and interdisciplinary collaboration are paving the way for the next generation of nanodrug delivery platforms. By addressing existing barriers and harnessing the potential of emerging technologies, the field is poised to make substantial contributions to the fight against cancer and the broader goals of precision medicine.

Future Trends

The future of nano drug delivery systems is marked by exciting innovations and multidisciplinary approaches that aim to address the current limitations while maximizing therapeutic efficacy. Among these advancements, the integration of artificial intelligence (AI) in nanotechnology is expected to revolutionize the design, development, and application of nanodrug delivery platforms. AI algorithms can analyze vast datasets to optimize nanoparticle size, shape, and surface chemistry, ensuring that they are tailored to target specific cancer types with high precision. For instance, AI models can predict the best combination of targeting ligands and drug payloads to improve tumor-specific accumulation and therapeutic outcomes *(Advanced Science, 2021)*. These advancements will enable personalized nanomedicine, where treatment strategies are customized based on individual patient profiles, genetic predispositions, and tumor microenvironments. Another promising trend is the development of multifunctional nanoparticles that integrate therapeutic, diagnostic, and monitoring capabilities into a single platform. Known as theragnostic, these systems allow for real-time imaging of drug distribution, monitoring of therapeutic efficacy, and dynamic adjustments to treatment regimens *(Nature Reviews Cancer, 2018)*. For example, liposomes and polymeric nanoparticles have been functionalized with imaging agents such as quantum dots and fluorescent dyes, enabling clinicians to track drug delivery and assess treatment responses in real-time. Gold nanoparticles, with their unique optical and photothermal properties, are particularly well-suited for theragnostic applications, offering simultaneous cancer ablation and diagnostic imaging through photoacoustic and computed tomography (CT) techniques *(ACS Nano, 2020)*.

In addition to theragnostic, hybrid nanosystems are emerging as a critical area of research. These systems combine multiple nanomaterials, such as liposomes with magnetic nanoparticles or gold nanoparticles with polymeric carriers, to leverage the strengths of each platform. For instance, hybrid nanoparticles can deliver chemotherapeutic agents while simultaneously applying localized hyperthermia or enabling imaging capabilities *(Journal of Controlled Release, 2021)*. Such multifunctionality is particularly valuable in addressing cancers with complex treatment requirements, such as glioblastoma and metastatic breast cancer.

The application of nanotechnology in combination therapies is also gaining momentum. Co-delivery of chemotherapeutics and immunomodulators via nanocarriers has shown significant potential in overcoming treatment resistance and enhancing therapeutic efficacy. For example, polymeric nanoparticles encapsulating both paclitaxel and immune checkpoint inhibitors have demonstrated synergistic effects in preclinical models, effectively reducing tumor burden while activating the immune system *(Trends in Biotechnology, 2021)*. Similarly, gold nanoparticles have been employed to deliver photothermal therapy alongside chemotherapeutic agents, creating a dual-modality approach that amplifies cancer cell death *(Biomacromolecules, 2021*).

Another critical area of future development is the use of

biodegradable nanomaterials to address concerns about long-term toxicity and accumulation. While traditional nanocarriers like iron oxide and gold nanoparticles offer significant advantages, their persistence in the body raises safety concerns. Researchers are now exploring materials such as polymeric micelles and lipid-based carriers that degrade into non-toxic byproducts after fulfilling their therapeutic roles *(Critical Reviews in Biotechnology, 2019)*. These advancements will not only improve patient safety but also facilitate regulatory approval and clinical translation of nanotechnology-based therapeutics. The incorporation of nanotechnology into emerging treatment modalities, such as gene editing and RNA-based therapies, is also expected to redefine the landscape of cancer treatment. Nanoparticles have shown promise as delivery vehicles for CRISPR-Cas9 systems and small interfering RNA (siRNA), enabling precise targeting of oncogenes and reversing drug resistance mechanisms at the genetic level *(Molecular Pharmaceutics, 2021)*. By protecting these fragile biomolecules from degradation and facilitating their intracellular delivery, nanocarriers can enhance the efficacy and specificity of genetic therapies.

Advancements in manufacturing technologies are another area of focus. Current challenges in scalability and reproducibility hinder the widespread adoption of nanodrug delivery systems. However, innovations in automated production methods, microfluidics, and green synthesis techniques are expected to address these barriers. For example, microfluidic platforms enable the precise fabrication of nanoparticles with uniform size and shape, ensuring batch-to-batch consistency *(Advanced Drug Delivery Reviews, 2019)*. Green synthesis methods, which use environmentally friendly processes and materials, are being developed to reduce production costs and environmental impact, making nanotechnology more accessible for large-scale applications *(Nature Nanotechnology, 2018)*.

Finally, the convergence of nanotechnology with wearable and implantable devices holds immense potential for continuous drug delivery and real-time monitoring. Implantable nanocarriers capable of releasing drugs in response to physiological changes, such as glucose levels or pH shifts, are being explored for personalized cancer therapy *(Journal of Nanoscience and Nanotechnology, 2020)*. Similarly, wearable devices integrated with nanotechnology can monitor treatment responses and provide feedback to clinicians, enabling more dynamic and adaptive treatment strategies.

In summary, the future of nanodrug delivery systems lies in the integration of advanced technologies and interdisciplinary collaboration. By addressing current challenges such as scalability, toxicity, and regulatory compliance, and embracing emerging trends such as AI-driven design, theragnostic, hybrid systems, and gene-based therapies, nanotechnology is poised to transform the landscape of cancer treatment. These advancements hold the promise of achieving truly personalized and precision medicine, significantly improving patient outcomes and quality of life.

References

1. Stephanie Tran, Peter Joseph De Giovanni, Brandon Piel, et al. Cancer nanomedicine: A review of recent success in drug delivery. Clin Transl Med. 2017; 6: 44.
2. Yihan Yao, Yunxiang Zhou, Lihong Liu, et al. Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. Front Mol Biosci. 2020; 7: 193.
3. Chehelgerdi M, Chehelgerdi M, Allela OQB, et al. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer. 2023; 22: 169.
4. Yanru Xin, Mingming Yin, Liyuan Zhao, et al. Recent progress on nanoparticle-based drug delivery systems for cancer treatment. Cancer Biol Med. 2017; 14: 228-241.
5. Yılmazoğlu E, Aytar EC, Karakuş S. Nanotechnology and Cancer Therapy Strategies. Springer Cham. 2024; 1-19.
6. Mariana Sell, Ana Rita Lopes, Maria Escudeiro, et al. Application of nanoparticles in cancer treatment: A concise review. Nanomaterials. 2023; 13: 2887.
7. Paola Sanchez-Moreno, Juan Luis Ortega-Vinuesa, Jose Manuel Peula-Garcia, et al. Smart drug-delivery systems for cancer nanotherapy. Curr Drug Targets. 2018; 19: 339-359.
8. Ganji Seeta Rama Raju, Eluri Pavitra, Ganji Lakshmi Varaprasad, et al. Nanoparticles mediated tumor microenvironment modulation: current advances and applications. J Nanobiotechnology. 2022; 20: 274.
9. Bao-Toan Nguyen Dang, Taeg Kyu Kwon, Sooyeun Lee, et al. Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy. J Control Release. 2024; 365: 773-800.
10. Yuki Agarwala, Timothy A Brauns, Ann E Sluder, et al. Targeting metabolic pathways to counter cancer immunotherapy resistance. Trends Immunol. 2024; 45: 486-494.
11. Yichen Guo, Yongjuan Li, Mengzhe Zhang, et al. Polymeric nanocarrier via metabolism regulation mediates immunogenic cell death with spatiotemporal orchestration for cancer immunotherapy. Nature Communications. 2024; 15: 8586.
12. Xiaoyou Wang, Chong Li, Yiguang Wang, et al. Smart drug delivery systems for precise cancer therapy. Acta Pharm Sin B. 2022; 12: 4098-4121.
13. Xiaoxiao Cheng, Qirong Xie, Yang Sun. Advances in nanomaterial-based targeted drug delivery systems. Front Bioeng Biotechnol. 2023; 11: 1177151.
14. Sangiliyandi Gurunathan, Min-Hee Kang, Muhammad Qasim, et al. NanoparticleMediated Combination Therapy: Two-in-One Approach for Cancer. Int J Mol Sci. 2018; 19: 3264.
15. Shi Su, Peter Kang M. Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems. Pharmaceutics. 2020; 12: 837.
16. Antonio Stefano Di. Nanotechnology in Targeted Drug Delivery. Int J Mol Sci. 2023; 24: 8194.

17. Xucheng Hou, Tal Zaks, Robert Langer, et al. Lipid nanoparticles for mRNA delivery. Nature Reviews Materials. 2021; 6: 1078-1094.
18. Melody Fulton D, Wided Najahi-Missaoui. Liposomes in Cancer Therapy: How Did We Start and Where Are We Now. Int J Mol Sci. 2023; 24: 6615.
19. Piotr Grodzinski, Moritz Kircher, Michael Goldberg, et al. Integrating Nanotechnology into Cancer Care. ACS Nano. 2019; 13: 7370-7376.
20. Ning Wang, Zhihan Wang, hihong Nie, et al. Biodegradable polymeric micelles coencapsulating paclitaxel and honokiol: a strategy for breast cancer therapy in vitro and in vivo. International Journal of Nanomedicine. 2017; 12: 1499-1514.
21. Bilan Wang, Shiqi Hu, Yan Teng, et al. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Signal Transduct Target Ther. 2024; 9: 200.
22. Marzena Szwed, Agnieszka Marczak. Application of Nanoparticles for Magnetic Hyperthermia for Cancer Treatment-The Current State of Knowledge. Cancers. 2024; 16: 1156.
23. Xubo Zhao, Jie Bai, Wenjing Yang. Stimuli-responsive nanocarriers for therapeutic applications in cancer. Cancer Biol Med. 2021; 18: 319-335.
24. Jinjun Shi, Philip Kantoff W, Richard Wooster, et al. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017; 17: 20-37.
25. Belén Begines, Tamara Ortiz, María Pérez-Aranda, et al. Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. Nanomaterials. 2020; 10: 1403.
26. Tingting Hu, Hanlin Gong, Jiayue Xu, et al. Nanomedicines for Overcoming Cancer Drug Resistance. Pharmaceutics. 2022; 14: 1606.
27. Ibtesam Waheed, Anwar Ali, Huma Tabassum, et al. Lipid-based nanoparticles as drug delivery carriers for cancer therapy. Front Oncol. 2024; 14: 1296091.
28. Yihan Yao, Yunxiang Zhou, Lihong Liu, et al. Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. Front Mol Biosci. 2020; 7: 193.
29. Ruirui Zhu, Fangyuan Zhang, Yudong Peng, et al. Current Progress in Cancer Treatment Using Nanomaterials. Front Oncol. 2022; 12: 930125.
30. Hongwen Lan, Muhammad Jamil, Gaotan Ke, et al. The role of nanoparticles and nanomaterials in cancer diagnosis and treatment: a comprehensive review. Am J Cancer Res. 2023; 13: 5751-5784.
31. Leming Sun, Hongmei Liu, Yanqi Ye, et al. Smart nanoparticles for cancer therapy. Signal Transduct Target Ther. 2023; 8: 418.
32. Fei Ye, Ying Zhao, Ramy El-Sayed, et al. Advances in nanotechnology for cancer biomarkers. Nano Today. 2018; 18: 103-123.
33. Christina Liu H, Piotr Grodzinski. Nanotechnology for Cancer Imaging: Advances, Challenges, and Clinical Opportunities. Radiol Imaging Cancer. 2021; 3: e200052.
34. Chunbai He, Jianqin Lu, Wenbin Lin. Hybrid nanoparticles for combination therapy of cancer. J Control Release. 2016; 219: 224-236.
35. Cancan Jin, Kankai Wang, Anthony Oppong-Gyebi, et al. Application of Nanotechnology in Cancer Diagnosis and Therapy - A Mini-Review. Int J Med Sci. 2020; 17: 2964-2973.
36. Manman Xu, Xinpu Han, Hongtai Xiong, et al. Cancer Nanomedicine: Emerging Strategies and Therapeutic Potentials. Molecules. 2023; 28: 5145.
37. Suhail Ahmad Mir, Laraibah Hamid, Ghulam Nabi Bader, et al. Role of Nanotechnology in Overcoming the Multidrug Resistance in Cancer Therapy: A Review. Molecules. 2022; 27: 6608.
38. Daniel Braatz, Mathias Dimde, Guoxin Ma, et al. Toolbox of Biodegradable Dendritic (Poly glycerol sulfate)-SS-poly(ester) Micelles for Cancer Treatment: Stability, Drug Release, and Tumor Targeting. Biomacromolecules. 2021; 22: 2625-2640.
39. Daoyuan Chen, Xuecun Liu, Xiaoyan Lu, et al. Nanoparticle drug delivery systems for synergistic delivery of tumor therapy. Front Pharmacol. 2023; 14: 1111991.
40. Huwyler J, Drewe J, Krähenbuhl S. Tumor targeting using liposomal antineoplastic drugs. Int J Nanomedicine. 2008; 3: 21-29.
41. Kawasaki ES, Player A. Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomedicine. 2005; 1: 101-109.
42. Chehelgerdi M, Chehelgerdi M, Allela OQB, et al. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer. 2023; 22: 169.
43. Gao Y, Wang, Zhang J, et al. Multifunctional nanoparticle for cancer therapy. MedComm. 2020; 4: e187.
44. García Domínguez DJ, López Enríquez S, Alba G, et al. Cancer Nano- Immunotherapy: The Novel and Promising Weapon to Fight Cancer. Int J Mol Sci. 2024; 25: 1195.
45. Alghamdi MA, Fallica AN, Virzì N, et al. The Promise of Nanotechnology in Personalized Medicine. J Pers Med. 2022; 12: 673.
46. Chenchen Li, Yuqing Li, Guangzhi Li, et al. Functional Nanoparticles for Enhanced Cancer Therapy. Pharmaceutics. 2022; 14: 1682.
47. Alexandra Pusta, Mihaela Tertis, Izabell Crăciunescu, et al. Recent Advances in the Development of Drug Delivery Applications of Magnetic Nanomaterials. Pharmaceutics. 2023; 15: 1872.
48. Wolfgang J, ParakAndre E, NelPaul S, et al. Grand Challenges for Nanoscience and Nanotechnology. ACS Nano. 2015; 9: 6637-6640.

49. Harshita Tiwari, Nilesh Rai, Swati Singh, et al. Recent Advances in Nanomaterials-Based Targeted Drug Delivery for Preclinical Cancer Diagnosis and Therapeutics. Bioengineering. 2023; 10: 760.

50. Omer Adir, Maria Poley, Gal Chen, et al. Integrating Artificial Intelligence and Nanotechnology for Precision Cancer Medicine. Adv Mater. 2020; 32: e1901989.